Combined and sequential treatment of oral and maxillofacial malignancies: An evolving concept and clinical protocol

Chinese Medical Journal

Volumn 121, Issue 19, 2008, Pages 1945-1952

  Zheng, Jia Wei ^a   Qiu, Wei Liu ^a   Zhang, Zhi Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Combined and sequential therapy; Multidisciplinary approach; Oral and maxillofacial malignancies; Oral cancer

Indexed keywords

ALPHA2B INTERFERON; ANTHRACYCLINE DERIVATIVE; BCG VACCINE; CARBOPLATIN; CETUXIMAB; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; INTERFERON; MELANOMA ANTIGEN; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; RECOMBINANT ALPHA2B INTERFERON; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACNE; ADJUVANT THERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOTHERAPY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TOLERABILITY; HEAD AND NECK CANCER; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOMA; MAXILLOFACIAL CANCER; MAXILLOFACIAL DISORDER; MEDLINE; MELANOMA; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PROGNOSIS; REVIEW; SALIVARY GLAND CARCINOMA; SKIN DISEASE; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

EID: 54349109898     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200810010-00017     Document Type: Review

References (27)

1. Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 2008; 30: 75-84.
2. Ord RA, Blanchaert RH Jr. Current management of oral cancer. A multidisciplinary approach. J Am Dent Assoc 2001; 132 Suppl: 19S-23S.
3. Lin GC, Qiu WL, Lu CY, Guo YQ, Cao Y, Guralnick W, et al. Long term follow-up results of Chinese prescription "Shen Yang" in the combined and sequential treatment of oral squamous cell carcinoma. Shanghai J Stomatol (Chin) 2003; 12: 321-323.
4. Jiang C, Ye D, Qiu W, Zhang X, Zhang Z, He D, et al. Response of lymphocyte subsets and cytokines to Shenyang prescription in Sprague-Dawley rats with tongue squamous cell carcinomas induced by 4NQO. BMC Cancer 2007; 7: 40.
5. Funk GF, Kamelt LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002; 24: 165-180.
6. Gibson MK, Forastiere AA. Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. Curr Opin Oncol 2004; 16: 220-224.
7. Vikram B, Strong EW, Shah JP, Spiro R. Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg 1984; 6: 720-723.
8. Tupchong L, Scott CB, Btitzer PH, Marcial VA, Lowry LD, Jacobs JR, et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 1991; 20: 21-28.
9. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
10. Adelstein DJ, Leblanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 2006; 24: 2624-2628.
11. Haddad R, Wirth L, Posner M. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs 2006; 11: 461-467.
12. Croll GA, Gerritsen GJ, Tiwari RM, Snow GB. Primary radiotherapy with surgery in reserve for advanced laryngeal carcinoma. Results and complications. Eur J Surg Oncol 1989; 15: 350-356.
13. Pignon JP, Baujat B, Bourhis J. Individual patient data meta-analyses in head and neck carcinoma: what have we learnt? Cancer Radiother 2005; 9: 31-36.
14. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
15. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RE, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
16. Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, et al. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol 2006; 42: 675-684.
17. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28.
18. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
19. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum- refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
20. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
21. Zhang B, Guan CC, Chen WT, Zhang P, Yan M, Shi JH, et al. A20 inhibits human salivary adenoid cystic carcinoma cells invasion via blocking nuclear factor-kappa B activation. Chin Med J 2007; 120: 1830-1835.
22. Mendenhall WM, Morris CC, Amdur RJ, Wenting JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 2005; 103: 2544-2550.
23. Douglas JG, Laramore GE, Austin-Seymour M, Koh W, Stelzer K, Griffin TW. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46: 551-557.
24. Rizk S, Robert A, Vandenhooft A, Airoldi M, Kornek G, Machiels JP. Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. Eur Arch Otorhinolaryngol 2007; 264: 587-594.
25. González-García R, Naval-Gias L, Martos PL, Nam-Cha SH, Rodríguez-Campo FJ, Muñoz-Guerra MF, et al. Melanoma of the oral mucosa. Clinical cases and review of the literature. Med Oral Patol Oral Cir Bucal 2005; 10: 264-271.
26. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801. J Clin Oncol 2001; 19: 2370-2380.
27. Majhail NS, Burns LJ. Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas. Curr Hematol Rep 2005; 4: 252-259.